Moneycontrol

Moneycontrol PRO

you are here: HomeNewsBusinessEarningsDishman Pharma eyes over 15% topline growth going forward

SHOW NAMES

Trending Topics

business

Dishman Pharma eyes over 15% topline growth going forward

Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.

first published: Nov 17, 2011 04:05 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347